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Quantifying perinatal transmission 
of Hepatitis B viral quasispecies by 
tag linkage deep sequencing
Yushen Du1,2, Xiumei Chi3,4,5, Chong Wang3, Jing Jiang6, Fei Kong3, Hongqing Yan3, Xiaomei 
Wang3,4,5, Jie Li7, Nicholas C. Wu1,8, Lei Dai1,9, Tian-Hao Zhang1,10, Sara Shu1, Jian Zhou11, 
Janice M. Yoshizawa11, Xinmin Li11, Debika Bhattacharya12, Ting-ting Wu1, Junqi Niu3,4,5 &  
Ren Sun1,2,9
Despite full immunoprophylaxis, mother-to-child transmission (MTCT) of Hepatitis B Virus still occurs 
in approximately 2–5% of HBsAg positive mothers. Little is known about the bottleneck of HBV 
transmission and the evolution of viral quasispecies in the context of MTCT. Here we adopted a newly 
developed tag linkage deep sequencing method and analyzed the quasispecies of four MTCT pairs 
that broke through immunoprophylaxis. By assigning unique tags to individual viral sequences, we 
accurately reconstructed HBV haplotypes in a region of 836 bp, which contains the major immune 
epitopes and drug resistance mutations. The detection limit of minor viral haplotypes reached 0.1% 
for individual patient sample. Dominance of “a determinant” polymorphisms were observed in two 
children, which pre-existed as minor quasispecies in maternal samples. In all four pairs of MTCT 
samples, we consistently observed a significant overlap of viral haplotypes shared between mother and 
child. We also demonstrate that the data can be potentially useful to estimate the bottleneck effect 
during HBV MTCT, which provides information to optimize treatment for reducing the frequency of 
MTCT.
Mother-to-child transmission (MTCT) of Hepatitis B Virus (HBV) poses a major obstacle in the mission to 
eliminate HBV. Despite full immunoprophylaxis (Hepatitis B immune globulin and vaccine series), perinatal 
transmission still occurs in 2–5% of HBV pregnancies1–5. Up to 90% of HBV-infected infants become chronically 
infected. Individuals with chronic HBV are at high risk of cirrhosis, liver failure, and hepatocellular carcinoma6, 7. 
It is thus essential to understand the factors that contribute to HBV MTCT. High HBV viral load and maternal 
HBeAg-positivity are the important virologic factors associated with immunoprophylaxis failure in children1, 2, 5, 7–9. 
Additionally, antibody escape viruses that harbor mutations in the major antigenic determinant (“a determinant”) 
region have also been detected in some immunoprophylaxis failures3, 10, 11.
HBV replicates with a mutation rate ~10 times higher than other DNA viruses due to a high replication rate 
with RNA as the intermediate and a low fidelity polymerase12–15. The high mutation rate of HBV causes diversifi-
cation from the transmitted viral species, yielding a large coexisting pool of genetically heterogeneous but closely 
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related viral genotypes within the same patient. The composition of viral quasispecies may be critical for disease 
progression and clinical prognosis16–22. For example, minor mutations in the basal core promoter and pre-core 
region have been described in the fulminant course of hepatitis B23. Pre-existing drug resistance mutations, even 
as the minority of the population, have been associated with treatment failure or rapid viral rebound after drug 
cessation19, 24, 25. HBV undergoes rapid intra- and inter-host evolution, especially under selection pressures such 
as immunoprophylaxis and drug treatment19. Investigating the dynamics of viral quasispecies evolution is crucial 
for the quantitative understanding of how HBV acquires drug resistance or develops antibody escape. Inter-host 
transmission is generally known as a severe bottleneck of viral evolution, which is proposed to play critical roles 
in the dynamics of the viral population in the infected individuals and populations26–28. Growing evidence shows 
that only one or a few founder viruses initiate infection for HIV and HCV26, 27 and then rapid adaptation and 
genetic evolution occur in each infected person. However, little is known about the bottleneck of HBV transmis-
sion and the evolution of HBV viral quasispecies between mother and child.
Next-generation sequencing (NGS) provides a rapid and high-throughput method to investigate the diver-
sity of viral populations. However, the short read length and high error rate of NGS poses challenges for the 
accurate assessment of viral quasispecies of sequences longer than the NGS reads. We recently developed a “tag 
linkage” method to overcome these two problems29. In brief, a 13-nucleotide random tag was assigned to each 
viral sequence. The long sequences were then divided into small amplicons that contained the same distinct tag, 
attached by PCR and circulation. The length of each small amplicon could be covered by NGS (Fig. 1). The impor-
tance of the randomized tags is two-fold. Firstly, tags can be used for sequencing error correction. The sequencing 
reads with the same tag are expected to originate from the same template molecule. Thus, the discordance of reads 
is largely attributed to sequencing error and can be corrected. Secondly, it can be used for haplotype reconstruc-
tion. Short reads with the same tag can be clustered to assemble the larger viral genome segments, which enable 
the determination of viral quasispecies.
In this study, we applied the “tag linkage” method and analyzed the quasispecies of four MTCT pairs that 
failed immunoprophylaxis. With extensive quality control, the accuracy was validated, which enabled the estab-
lishment of the sensitivity of our approach. We reconstructed 836 bp HBV sequences covering the majority of 
the reverse transcriptase (RT) domain and overlapping S gene with a detection limit of 0.1% of the viral popu-
lation in each infected individual. Previously identified vaccine escape mutations in the “a determinant” region 
were observed to be dominant in two children samples. We also observed significant overlap of viral haplotypes 
between maternal and children samples. Phylogenetic analysis and mathematical simulations suggested that the 
transmission bottleneck of HBV MTCT is loose, which is in drastic contrast to recent findings of severe transmis-
sion bottleneck in HIV and HCV26, 27.
Materials and Methods
Study subjects and samples. The blood samples were collected from patients at the 1st hospital of Jilin 
University from July 2012 to February 2015. The study’s protocol was approved by the Research Ethics Committee 
of the hospital. Informed consents were obtained from patients. This study screened HBsAg positive pregnant 
females who were followed up by the Department of Hepatology. The infants of HBsAg positive mothers received 
HBV immunoprophylaxis consisting of Hepatitis B immune globulin (HBIG, 100 IU) and 0.5 ml of the pediatric 
formulation of HBV vaccine (20 ug, S20133009, Dalian Hissen Bio-pharm. Co., Ltd, Dalian, China). Within two 
hours after birth, the vaccine and HBIG were given via intramuscular injection. Second and third doses of vaccine 
were given 1 and 6 months after birth. Blood samples were drawn from the children within 30 to 37 days after 
the last dose of the vaccine at 7 months ± 1 week of age, and from mothers at delivery. To re-evaluate the positiv-
ity of HBsAg, blood samples were drawn from the children again at 12 months of age. HBV serology was done 
by chemiluminescence technique (Abbott, in the Key Laboratory of Infectious Diseases, Jilin University). HBV 
viral load was quantified using the COBAS AmpliPrep/COBAS TaqMan assay (Roche Diagnostics, Grenzach, 
Germany). HBV DNA was extracted from 400ul serum using the EZbead System-32 auto-extraction-system 
(Haoyuan Biotech, Shanghai, China). In the cohort, 1583 pregnant women were identified as HBsAg positive 
during the enrollment phase, among which 785 mother-child pairs were successfully followed. 14 children were 
detected to be HBsAg positive at 7 months ± 1 week of age, and were confirmed to be positive at 12 month of age. 
Thus, the HBsAg positivity rate of the cohort was 1.8% (14/785). Out of the 14 HBsAg positive children, only 6 
had enough blood sample for DNA extraction30. All of the corresponding 14 maternal samples had high plasma 
HBV viral load (>107 IU/ml). 2 out of the 6 children samples failed to be amplified due to low viremia. Thus, 
the remaining four mother-child pairs (8 samples of the leftovers) were utilized for the current study of the HBV 
quasispecies transmission. The sequencing and data analyses were done at UCLA with the approval from UCLA 
IRB. All methods performed were in accordance with the relevant guidelines and regulations.
Tag-linkage sequencing of HBV RT/S region. For all 8 samples, a 13-bp random nucleotide tag and 
a unique population ID were linked on the amplified RT/S region through PCR. 500ng extracted DNA were 
used as a template for amplification. Each sample was then diluted to ~10,000 dsDNA/ul through serial dilu-
tion. Approximately 10,000 DNA molecules were re-amplified and separately amplified with different primer 
sets rendering two small products with length ~450 bp and ~900 bp. Small products were ligated with a 15 bp 
linker. Ligations were performed in a 100 ul system with 0.1 ng total DNA to maximize self-ligation. Ligation 
products were then amplified to make the final ~430 bp amplicons. Finally, sequencing adaptors were added onto 
amplicons for Illumina sequencing. All the primers were designed to be primed at the conserved regions of HBV 
genome (Supplementary methods).
Sequencing and Data analysis. Samples were sequenced with 1.5 lanes of Illumina Miseq PE250 (MiSeq 
Reagent Kit v2, MS-102–2003).
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Sequencing data were analyzed with customized python scripts (available upon request). Sequencing reads 
were first matched to the primer sequence and then separated into different amplicons accordingly. Forward and 
reverse reads were paired and aligned. For each amplicon, sequences with the same population ID and the same 
randomized tag were clustered together. Within each cluster, all the sequences were aligned and sequences with 
different lengths (insertions or deletions) were filtered out. For sequencing error correction, mutations were iden-
tified if they occurred in more than 60% of reads within one cluster based on consensus of each patient sample. 
Haplotypes were then assembled if three or more amplicons occurred for the same tag.
Statistic and phylogenetic analysis. Shannon entropies were calculated using vegan package in R lan-
guage. Multiple sequence alignment was performed with Muscle31. Phylogenetic trees of each pair of MTCT 
patients were generated using PhyML under the GTR substitution model. Bootstraps were performed 100 times 
to examine the confidence of the trees32, 33. For better visualization, we drew the branch width as proportional to 
the bootstrap value, and the thickest branch with a bootstrap value equal to 1. Highlighter plots were generated 
Figure 1. Tag-linkage sequencing of HBV RT/S region. (a) A schematic presentation of the HBV viral 
genome region (polymerase gene) that was processed and reconstructed using the tag-linkage method. 836 bp 
of polymerase gene (blue box) was recovered, including the majority of the reverse transcriptase domain 
(overlapping S gene) and part of the RNase H gene. (b) A schematic presentation of the experiment flow for 
tag linkage deep sequencing. 1) HBV sequences were amplified from viral DNA extracted from patient plasma 
using primers targeting conserved region. Tags were added onto each molecule for sequencing error correction 
and haplotype reconstruction. 2) Different length of sequences (covering different number of non-overlapping 
small amplicons) were amplified from ~10,000 molecules. 3) Amplified sequences were ligated. 4) Small 
amplicons were further amplified for sequencing.
www.nature.com/scientificreports/
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using the highlighter tool from http://www.hiv.lanl.gov/34. The numbering of the viral haplotypes (P1M.1, PM1.2, 
et al.) was ranked in accordance to the frequency in the corresponding patient sample, with the number 1 haplo-
type (example: P1M.1) being the dominant species. All the haplotypes >0.1% were considered for phylogenetic 
analysis.
Estimation of the transmission bottleneck. Random multinomial samplings of transmitted viral hap-
lotypes were performed based on the frequency distribution of the mother’s haplotypes27. Viral particles were 
randomly generated with a probability proportional to the relative frequency of each haplotype. The number 
of haplotypes shared between the mother and the child was defined as the threshold (N). For a given number 
of transmitted infectious particles, we performed 1000 samplings. In each sampling, we counted the number of 
haplotypes being transmitted. Assuming a given number of transmitted infectious particles, we then calculated 
the percentage of times (out of 1000 simulations) that the probability of successfully transmitting was equal or 
more than the number of viral haplotypes shared between mother and child (N). To give an estimate for the lower 
bound of transmission bottleneck, we reported the number of transmitted viral particles that the probability of 
successfully transmitting the shared haplotypes is larger than 5%. In this calculation, we assume that the diversity 
of transmitted haplotypes does not impact the efficiency of transmission.
Nucleotide sequence accession numbers. Raw sequencing reads were deposited at NCBI sequence read 
archive (SRA) with Bio Project ID: PRJNA309553.
Results
Clinical and laboratory information. Four mother-child pairs that failed HBV immunoprophylaxis were 
available for sequencing analysis, from a cohort that identified 1583 pregnant women as HBV-positive during 
July 2012 to February 2015 (Method). All 8 individuals were infected with subtype C HBV virus, which is the 
dominant subtype for Chinese patients. Patient information and HBV statuses are shown in Table 1. All 4 moth-
ers were HBeAg positive, and had high HBV viral load (>108 IU/ml). No antepartum HBV antiviral therapy was 
received. HBV immunoprophylaxis of children included HBIG (100IU) and 3 doses of pediatric formulation of 
HBV vaccine (0.5 ml). The first doses of the vaccine and HBIG were administered within two hours after birth. 
The second and the third dose of HBV vaccine were given at 1 and 6 months post birth, respectively. Blood sam-
ples were collected from mothers at delivery, and from the children within 30 to 37 days after the last dose of the 
vaccine at 7 months ± 1 week of age.
Reconstruction of HBV viral RT/S region with tag-linkage method. We analyzed an 836 bp region 
of the HBV genome covering the majority of polymerase reverse transcriptase domains and the overlapping S 
gene [Fig. 1A]. This is a diverse region on HBV genome and responded to HBs antibody selection and drug resist-
ance [Supplementary Figure S1]. The “tag-linkage” method, which was recently established and validated, was 
used in order to get high quality viral haplotypes [Fig. 1B]29. Briefly, HBV viral DNAs were extracted and ampli-
fied from the sera. Tags containing 13 random nucleotides were then linked to DNA molecules through limited 
cycles of PCR amplification. The tagged products were then divided into two ~430 bp non-overlapping amplicons, 
which could be covered by combining forward and reverse reads of Illumina Miseq PE250. The unique tag from 
the full-length product was linked to each small amplicon through circularization based PCR-amplification. For 
each patient sample, ~10,000 tagged DNA molecules were processed and deep sequenced. The 13 random nucleo-
tide tag allowed the maximum complexity to be 6.7e7 (413), ensuring the separation of ~10,000 molecules through 
the recognition of tag sequences. All the primers were designed to be primed at the conserved regions of HBV 
genome (supplementary method). We achieved at least 100,000 reads coverage for each amplicon, which pro-
vided ~10 reads per viral sequence for sequencing error correction using the tag. ~3,000–5000 unique tags (30–
50% of input tagged DNA molecules) were detected for each amplicon post quality filtering and error correction.
P1M P1C P2M P2C P3M P3C P4M P4C
HBV DNA (IU/ml) 1.70 × 109 1.06 × 108 3.40 × 108 6.06 × 107 1.03 × 108 1.97 × 108 1.70 × 109 2.64 × 108
HBsAg (IU/ml) >250 >250 >250 >250 >250 >250 >250 >250
HBsAb (mIU/ml) 0 0.33 0.35 0.06 0 0 0.18 0
HBsAb (positivity) (−) (−) (−) (−) (−) (−) (−) (−)
HBeAg (S/CO) 1182.52 324.862 1271.72 244.589 575.309 430.197 1178.93 161.91
HBeAg (positivity) (+) (+) (+) (+) (+) (+) (+) (+)
HBeAb (S/CO) 95.21 40.25 97.96 31.6 28.15 22.96 96.43 22.34
HBcAb (S/CO) 6.37 5.55 7.95 4.62 9.17 10.35 5.79 9.4
Dose of Vaccine / 20ug / 20ug / 20ug / 20ug
Number of 
Vaccinations / 3 / 3 / 3 / 3
Age 27 years 7 month ± 1 week 33 years 7 month ± 1 week 25 years 7 month ± 1 week 27 years 7 month ± 1 week
Table 1. Patient Information. Note: P1M is mother of the first patient pair, P1C is the child first patient pair. 
And so on.
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To examine the quality of our “tag-linkage” method, we performed multiple steps of quality control. Firstly, 
two HBV clonal plasmids were used as input instead of patient DNA to examine the processing errors (PCR and 
sequencing errors). For both plasmids, ~96% reconstructed full-length sequences were correct. More than 95% 
of the remaining errors resulted in false positive haplotypes occurring at ≤ 0.1%. Thus, we set 0.1% as our detec-
tion limit for a minor viral haplotype [Fig. 2A]. Secondly, the accuracy and sensitivity of our method was exam-
ined by mixing 5 different HBV clonal plasmids at equal or different ratios as input. When mixing 5 plasmids 
in equal ratio (20% of each), we successfully detected all 5 different haplotypes as dominant species [Fig. 2B]. 
There were some distortions of detected frequency versus actual frequencies, which might have come from PCR 
bias. We also mixed 5 plasmids with log ratio, with the lowest one at ~0.01%. As expected, haplotypes >0.1% 
were confidently detected, while the other two at 0.1% and 0.01% were mixed with noise [Fig. 2C]. Thirdly, a 
biological duplicate of P1M (pair 1 mother) sample from the DNA extraction step was performed. All the viral 
haplotypes detected >0.1% were repeatedly detected in the biological duplicate, with a ranking correlation coef-
ficient of 0.87 [Fig. 2D]. Lastly, clonal sequencing for P1M sample was conducted to examine the correlation 
by the tag-linkage sequencing method. We randomly picked 40 colonies and detected 4 different haplotypes. 
Three of the haplotypes were observed by tag-linkage sequencing method, and the frequency was close to clonal 
sequencing results [Fig. 2E]. The missing haplotypes were different by one base pair when compared to the closest 
viral sequence in the quasispecies reconstructed by our approach. The traditional clonal sequencing data verified 
Figure 2. Quality control examination of the tag-linkage method. (a) Two HBV clonal plasmids were used 
to examine processing errors. Fractions of reconstructed sequences are shown. More than 95% of errors 
result in false positive haplotypes that occur ≤0.1%, thus justifying 0.1% as our detection limit for minor viral 
haplotypes. (b) Successful detection of 5 different haplotypes is shown upon mixture of 5 plasmids in equal 
ratio. (c) Detection of 5 different haplotypes is shown upon mixing 5 plasmids in log ratio. The red dashed 
line represents the highest frequency of viral haplotypes detected in this sample which does not belong to the 
parental 5 plasmids, representing the level of noise. (d) Correlation of viral haplotypes of biological duplicates of 
mother sample of patient 1. (e) Correlation between clonal sequencing and tag-linkage sequencing. 40 random 
colonies were selected and their haplotype sequences were analyzed via both methods.
www.nature.com/scientificreports/
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our tag linkage sequencing method. The above results establish the sensitivity and accuracy of our tag linkage 
sequencing approach to detect HBV haplotypes.
Characteristics of Intra-host diversity of HBV viral quasispecies. For the 8 samples from four 
mother-child pairs, the number of viral sequences that were successfully assembled for each sample is shown in 
Fig. 3A. Based on the results from control plasmids, we focused our analysis on the viral sequences that occurred 
>0.1%, which were defined as “high quality quasispecies”. Up to 33 different high quality haplotypes were 
detected within one sample for the sequenced region, which are shown in Fig. 3B.
To examine the diversity of intra-host viral quasispecies, the normalized Shannon entropy (Sn) was calculated 
for each patient sample. Sn ranged from 0.17–0.55, depending on patients [Fig. 3C]. There was no significant 
difference of Sn between samples from mother and child (p = 0.57, two-tailed T-test). For each mother-child pair, 
we constructed the phylogenetic tree by PhyML using GTR substitution model. Bootstraps were performed 100 
times to examine the confidence of the trees32, 33. The branch width of the tree was proportional to the bootstrap 
value, with the thickest branch having a bootstrap value equal to 1. Bootstrap values were also labeled for major 
Figure 3. Characteristics of Intra-host diversity of HBV viral quasispecies. (a) Numbers of viral sequences 
that were detected for each sample. P1 stands for the mother-child pair 1, and there are four pairs (P1 to P4). 
M stands for maternal sample, and C stands for child sample. (b) Numbers of high quality viral haplotypes 
detected in each infected individual. (c) Bar plots are shown for the normalized Shannon entropy of viral 
quasispecies for each patient. (d) Phylogenetic tree and highlighter plot are shown for viral haplotypes of each 
mother-child pair. 100 bootstraps were performed. The tree branch width is proportional to the bootstrap value.
www.nature.com/scientificreports/
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branches. The numbering of viral haplotype for each patient was ranked by the corresponding frequency. We 
did not observe any data that suggested a single founder from the maternal samples established the phylogeny 
of the children’s samples. Instead, the viral haplotypes are mixed and shared between mothers and children for 
these four patient pairs. Paired with the phylogenetic tree, highlighter plots were also generated to demonstrate 
the mutations occurring in each haplotype, using the dominant haplotype from maternal sample as the master 
sequence34.
Genetic drift and transmission bottleneck of HBV quasispecies in MTCT. To further investigate the 
relationships between the viral haplotypes between maternal and child samples, scatter plots were generated for 
haplotype frequencies for each mother-child pair. We observed that pair 2 and pair 4 shared a significant portion 
of same haplotypes with similar frequencies, while the major haplotype of mother and child were different for 
pair 1 and pair 3 [Fig. 4A].
Figure 4. Genetic drift and transmission bottleneck of HBV quasispecies in MTCT. (a) The occurrence 
frequency of each viral haplotype is shown as a scatter plot in the log scale. Haplotypes that were not detected 
in patients were plotted as −4. (b) Relationships of viral haplotypes detected in mother and their child samples 
for pair 1 and 3. Each color represents one HBV haplotype and their percentage corresponds to its abundance in 
the viral population in the indicated individual. G145E and G145A were minor quasispecies in mother samples 
and became dominant in the corresponding child samples. (c) Shannon entropy of the “a determinant” region is 
shown for each maternal sample. (d) Frequencies of detected “a determinant” mutations are shown for maternal 
sample. (e) Venn diagrams summarize the overlapping viral haplotypes between maternal and child samples. 
(f) Simulation result depicts the probability of successful transmission of the shared viral haplotypes between 
mother and child, dependent on the transmission bottleneck. X-axis represents the number of transmitted 
viruses being sampled in simulations. Y-axis represents the probability of transmitting equal or more than the 
number of viral haplotypes shared between the mother and the child.
www.nature.com/scientificreports/
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Newly emergent dominant mutations in the child sample for pair 1 and pair 3 were examined for selec-
tive sweeping of certain beneficial mutations. Notably, mutations at position G145 harbored the most change. 
G145A became dominant in the child from pair 3, and G145E for the child from pair 1 [Fig. 4B]. We detected 
single mutations: G145R, G145K and G145E, as well as double mutations: D144G-G145E and K141R-D144N 
that occurred more often in children samples. These mutations are located at the 2nd loop of “a determinant” 
region, and are responsible for escaping from hepatitis B surface antibody recognition35–39. The disruption of local 
structures might change the immunological characteristics of HBsAg and diminish the binding of the antibody, 
resulting in vaccine escape. Both G145A12, 40–44 and G145E45, 46 have been detected in HBsAg-positive vaccinated 
individuals, which are attributed to their antibody escape phenotype. Thus, the distinct proportion of viral qua-
sispecies for pairs 1 and 3 are most likely attributed to the growth advantage of “a determinant” mutations. We 
further investigated if there was any relationship between the transmission of “a determinant” mutations and the 
minority variant quasispecies in maternal samples. The entropy of “a determinant” domain was larger for patient 
1 and 3, suggesting that these two maternal samples have higher diversity at the antibody recognition region 
[Fig. 4C]. G145A and G145E were detected in maternal samples with a slightly higher percentage in patients 1 
and 3. However, all of them were minor mutations that occurred at a frequency of <1% [Fig. 4D].
Despite the dominance of “a determinant” region mutations for pair 1 and 3, we observed that the overall viral 
haplotypes were significantly overlapped between mother and child of each pair. For all pairs, close to or more 
than 50% of viral haplotypes in the maternal samples were also observed in the child samples [Fig. 4E]. Although 
there are limitations with our current samples and size of the cohort (discussion), with relatively accurate meas-
urement of viral quansispecies, it might be informative for assessing the transmission bottleneck of HBV MTCT. 
Growing evidence shows that only one or a few viral particles initiate infection during HIV and inter-host trans-
mission during HCV26, 27. Supporting evidence comes from the low viral sequence diversity detected immediately 
after transmission. However, this issue has not been well defined for HBV. To estimate the HBV transmission 
bottleneck, we applied random multinomial samplings to simulate the process of MTCT (methods)3, 27, 28. It is 
estimated that 50~200 infectious HBV viruses need to be transmitted so that the probability of successfully trans-
mitting the shared haplotypes is larger than 5% [Fig. 4F]. This result indicates that the MTCT bottleneck for HBV 
might be fairly loose for the four MTCT cases studied her. However, due to the limited number of patient samples 
available, the late time point that children samples were collected and non-whole genome sequencing of current 
study, further investigation with a higher quality of whole genome sequencing data is needed to further quantify 
the genetic bottleneck of MTCT in HBV.
Discussion
Over 240 million people are chronically infected with HBV, and ~1 million deaths per year are attributed to HBV 
related diseases6. Mother to child transmission of HBV virus is a leading cause of chronic infection. HBV immu-
noprophylaxis has greatly reduced the MTCT rate from ~50% to 2–5%2, 40. However, due to the large number 
of HBV infected people, the 2–5% immunoprophylaxis failure remains an important public health issue. For 
the current cohort, 1583 pregnant women were identified as HBsAg-positive and 785 mother-child pairs were 
followed up. 14 children were detected to be HBV infected. We analyzed the HBV quasispecies evolution in the 
4 mother-child transmission pairs that had enough serum for successful PCR amplification. The tag-linkage 
method enabled us to accurately measure mutations in minor subpopulations and assemble long viral haplotypes. 
We observed that “a determinant” mutations were dominant in two children samples that pre-existed as minor 
quasispecies in corresponding maternal samples. Besides the selection sweep of “a determinant” mutations, lim-
ited evolution or genetic drift was observed in the viral population from mother to child. Phylogenetic analysis 
and mathematical simulation estimated that 50~200 infectious HBV viruses need to be transmitted, suggesting a 
loose bottleneck during HBV MTCT.
Mutations in HBV surface protein are known to play an important role in antibody escape and vaccine failure. 
Accurate identification of minor mutations is critical for determining the relationship between pre-existence 
of mutations in maternal samples with the dominance of mutations in child samples. Taking advantage of the 
tag-linkage method, we were able to detect minor haplotypes at a frequency of ~0.1% by correcting sequencing 
errors. We observed a slightly higher diversity at “a determinant” regions and a higher frequency of possible vac-
cine escape mutations in mothers who transmitted mutated strains to their children.
Our data and simulations suggest that 50~200 viruses need to be transmitted to generate the observed qua-
sispecies pattern. This contrasts with HIV and HCV, in which only one or a few founder viruses can get through 
the severe MTCT bottleneck and establish infection. However, it is similar with the estimation for influenza 
transmission26–28. A number of factors might contribute to the loose bottleneck with a transmission of multiple 
founder viruses. Firstly, all 4 mothers in our study were HBeAg positive, with HBV copy number >108 /ml. Rapid 
viral replication increases the risk of intrauterine transmission through the induction of T cell tolerance in utero2. 
Moreover, the high viral load of the mother may expose the newborn to a large quantity of viruses that exceed the 
neutralizing ability of antibodies. Furthermore, recent studies suggested HCV and HIV founder viruses are char-
acterized with strong immune escape properties due to the robust selection during transmission26, 47–50. However, 
natural infection of HBV contains a HBeAg-positive immunotolerant phase for mother and child51. The lack 
of immune pressure may cause a lack of selection in the founder virus. Finally, HBV has much higher infec-
tivity (~50–100 times higher than HIV) that enable the transmission of large amount of viruses through blood 
exchange52. The MTCT without immunoprophylaxis for HBV is >90%, compare to 5–7% for HCV and 15–45% 
for HIV53–55.
The loose bottleneck that is observed here might also provide support and guidance for the treatment of HBV 
during the third trimester. If actual transmission of virus is partly due to the inefficient neutralizing ability of anti-
bodies, then the quantity of transmitted virus might be proportional to maternal viral loads. In this scenario, for 
patients with HBV copy number >108 /ml, it might be necessary to reduce the viral load more than 50~200 fold 
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to reduce the possibility of MTCT. This hypothesis is also consistent with our cohort data, in which all the MTCT 
cases occur in the mother sample with HBV copy number >107 /ml.
Decreasing the viral copy number through drug treatment during the third trimester might be efficient in 
reducing MTCT rate56–58. One major concern of drug treatment was the selection of drug resistant mutations 
in the reverse transcriptase and the corresponding HBs mutations that confer antibody escape. To assess the 
possibility of drug resistance, we analyzed the frequency of well-known drug (Nucleos(t)ide Analogues) resistant 
mutations on position rt171, rt173, rt180, rt181, rt204 in maternal samples [Supplementary Figure S2]. They only 
existed at very low frequencies (<0.2%). Moreover, we did not detect the co-occurrence of drug resistant muta-
tion and antibody escape mutation on one haplotype in any patient samples.
As the first comprehensive examination of the viral quasispecies during MTCT, additional studies are required 
to address several limitations of this study. Firstly, this study was restricted to subtype C. It is to be determined 
whether the loose bottleneck will be observed for patients with other subtypes of HBV infection. Secondly, the 
children samples were collected ~7 months after birth, which may already contain mutations compared with 
the viral haplotypes immediately after transmission. Based on the reported HBV mutation rate, 1 mutation at 
most, would occur in the region that was examined during the 7 months12–15. Thus, we assume it would not have 
severe impact on the main conclusion of our analyses. We cannot rule out the possibility of convergent evolution 
or extinction of viral haplotypes in children, but the substantial overlap of viral haplotypes between mother and 
child even after 7 months post-birth leads to the observation of a loose transmission bottleneck. The large number 
of quasispecies deduced from a long segment of the viral genome suggested that these quasispecies were not gen-
erated de novo in children. The most possible explanation is that they were transmitted from their mothers, still 
persisted in the infant at month 7 post birth, and evolve to have some diversity in the infants. More children sam-
ples collected immediately after birth are most suitable to rarify our observation. Lastly, although there is much 
improvement in the accuracy and sensitivity of the tag-linkage method on detecting minor viral haplotypes, it 
has drawbacks with extensive PCR amplification that might create some distortion of the ratio of a subset of viral 
haplotypes. A transposon-based system or endonuclease system might be incorporated to control the bias during 
PCR amplification, though it is more technically intensive59.
In summary, we comprehensively and quantitatively analyzed the HBV viral quasispecies evolution in 
mother-child transmission samples with the “tag-linkage” method. Dominance of “a determinant” mutations was 
observed and a significant overlap of viral haplotypes was shared between mother and child, suggesting the trans-
mission bottleneck during MTCT might be loose. Further studies with more MTCT samples collected shortly after 
birth and with different serotypes should be studied to verify our observation. Moreover, the “tag-linkage” method 
presented here is widely applicable to study infections, transmission and evolution of other types of viruses.
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